A Long-Term Follow-Up Study of Participants Treated With A2 Biotherapeutics (A2 Bio) Gene Therapy (GT) Products
This protocol is to ensure consistent long-term follow-up for delayed safety events in participants who received A2 Bio gene therapy (GT) products.
Checked against the public recordLast updated May 20, 2026 · Source: ClinicalTrials.gov
What this study is about
- Purpose
- Not specified
- Study type
- Observational
- Phase
- Not applicable
- Sponsor
- A2 Biotherapeutics Inc.
- Interventions being studied
- Other: No additional intervention administered in this long term follow-up study
How this study is categorized
These labels come from structured fields and exact terms in the public record.
Who may be able to participate
Inclusion Criteria: 1. Received any amount of A2 Bio GT product on a previous A2 Bio interventional study 2. Able to provide written informed consent for this long-term follow-up study 3. Able to comply with study requirements Exclusion Criteria: 1\. There are no specific exclusion criteria for this study
Important: This is the sponsor’s public criteria, not a determination of eligibility. The study team must review your individual situation.
U.S. locations
- Banner HealthGilbert, Arizona
- Mayo ClinicRochester, Minnesota
- NYU Langone Medical CenterNew York, New York
Source and freshness
Processed from ClinicalTrials.gov. Last public update: May 20, 2026. Always confirm current availability with the study team.